The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions

Current Drug Metabolism

Volumn 2, Issue 3, 2001, Pages 299-314

  Bachmann, K A ^a   Ghosh, R ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CALCIUM ANTAGONIST; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; DIHYDROPYRIDINE; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; KETOCONAZOLE; MICONAZOLE; NEVIRAPINE; NEW DRUG; NICARDIPINE; NORFLUOXETINE; PHENYTOIN; RITONAVIR; ROFECOXIB; SULFAPHENAZOLE; SULFONAMIDE; THEOPHYLLINE; TOLBUTAMIDE; TOPIRAMATE; WARFARIN; ZONISAMIDE;

ACCURACY; ANIMAL; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSPORT; EXPERIMENT; GASTROINTESTINAL TRACT; HEPATOBILIARY SYSTEM INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHODOLOGY; PHARMACOKINETICS; PREDICTION; RETROSPECTIVE STUDY; SCREENING; STATISTICAL ANALYSIS; STATISTICAL MODEL; TECHNIQUE;

ANIMALS; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; SPECIES SPECIFICITY;

EID: 0034862327     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389200013338504     Document Type: Article

References (74)

1. Integrating drug discovery and development
2. Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the Abbott Laboratories experience
3. Preclinical drug metabolism in the age of high-throughput screening. An industrial perspective
4. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery
5. Sample pooling to expedite bioanalysis and pharmacokinetic research
6. Plasma pooling methods to increase throughput for in vivo pharmacokinetic screening
7. Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated dose-finding trials
8. Interspecies pharmacokinetic scaling and the Dedrick plots
9. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species
10. Interspecies extrapolation of pharmacokinetics
11. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm
12. Interspecies scaling: Role of protein binding in the prediction of clearance from animals to humans
13. Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics
14. Interspecies scaling: Prediction clearance of drugs in humans: Three different approaches
15. Pharmacokinetics and molecular detoxication
16. Risk assessment of environmental chemicals
17. Interspecies scaling of toxicity data
18. Scaling basic toxicokinetic parameters from rat to man
19. Estimating xenobiotic half-lives in humans from rat data:Influence of log P
20. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
21. Critique of prospective allometric scaling;does the emperor have clothes?
22. First time in human for GV 196771: Interspecies scaling applied on dose selection
23. The pharmacokinetic principles behind scaling from preclinical results to Phase I protocols
24. First-time-in-human dose selection: Allometric thoughts and perspectives
25. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations
26. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist
27. Physiological pharmacokinetic models: Some aspects of theory, practice, and potential
28. Physiologically based pharmacokinetic modeling: Principles and applications
29. Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals
30. Extrapolation of physiological parameters for physiologically based simulation models
31. Physiologically based pharmacokinetic modeling as a tool for drug development
32. Advances in vitro drug metabolism screening
33. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver. Studies with induced livers involving diazepam
34. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
35. Predicting the hepatic clearance of xenobiotics in humans from in vitro data
36. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
37. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum
38. Unbound total (plasma) clearance approach in interspecies pharmacokinetics correlation: Theophylline-cimetidine interaction
39. Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants
40. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data
41. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions
42. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions
43. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitripytline and fluoxetine
44. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone
45. Predicting drug interactions and pharmacokinetic variability with in vitro methods: The olanzapine experience
46. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-menten model
47. Human cytochrome P4503A4: In vitro drug-drug interaction patterns are substrate-dependent
48. Elucidation of distinct ligand binding sites for cytochrome P4503A4
49. Nonspecific binding of drugs to human liver microsomes
50. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples
51. Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone
52. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
53. Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog, and human
54. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol
55. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P450 in rats
56. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: Can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
57. Pharmacokinetics and metabolism in early drug discovery
58. Expression and regulation of hepatic drug and bile acid transporters
59. Hepatic sinusoidal membrane transport of anionic drugs mediated by anion transporter Npt1
60. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary exrection of drugs
61. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
62. Drug metabolism in hepatocyte sandwich cultures of rats and humans
63. Use of sandwich-cultured hepatocytes to predict in vivo biliary drug clearance
64. Prediction of CYP-mediated drug interactions due to irreversible inhibition
65. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling
66. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin